Meeting the Patient Before the Label

What changes at approval is not the product and not the patient. It is who is looking at them, and what they are counted for.

Supporting a program from R&D finance through launch, I carried the clinical understanding of the patient into the commercial models, because the gap between how R&D understands a patient and how Commercial understands a customer was visible to me and almost nobody else. I should have documented that gap so it stopped being tacit.

Decision context

I came into pharmaceuticals through oncology R&D, supporting an alpha-emitting radiopharmaceutical, and followed its pivotal trial from the clinical side into commercial launch.

That sequence matters more than it sounds. Most finance people meet a product after it has a label, a forecast and a price. I met this one while it was still a hypothesis being tested in men who had run out of options.

My authority

None of the decisions here were mine to make. I was in R&D finance, supporting a program. What I had was access to both rooms during a period when almost nobody has access to both, and a choice about whether to carry what I learned in one into the other.

What I built

• Continuity of assumption. The commercial model inherited the clinical understanding of the patient rather than replacing it with a market-sized abstraction.
• A handoff that was not a handoff. I kept the R&D relationships after the program moved, so the questions that surfaced later had somewhere to go.

The trade-off

What I would do differently

I would have written the difference down. The gap between how R&D understands a patient and how Commercial understands a customer was visible to me and to almost nobody else, and I treated it as something I understood rather than something the organization needed documented. It is where most of the friction in this industry is born, and I let it stay tacit for years.

The product does not change at approval. The patient does not change at approval. What changes is who is looking at them and what they are counted for.

Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.